Jaydutt V Vadgama, PhD
Title Professor
Institution Charles R. Drew University of Medicine and Science
Department Internal Medicine
School College of Medicine
Address 1731 E. 120th Street, Hawkins Building


Telephone (323) 563-9397
Fax
Email
Overview
Dr. Vadgama is the Vice President for Research and Health Affairs at CDU. He is a full Professor of Medicine at CDU and at the UCLA David Geffen School of Medicine in the Department(s) of Internal Medicine. Dr. Vadgama has provided significant leadership in growing and sustaining research at CDU over the last two decades. Dr. Vadgama has several additional administrative responsibilities that include Chair of the Institutional Space Committee, Chair of the PhD Planning Committee, establishing the Intellectual Property/Patent Committee at CDU, Institutional Official for IACUC and chairing several Task Force committees.

Leadership Experience: Dr. Vadgama continues to serve as Division Chief, Center Director, Vice President, member of the President’s Executive Team and the Provost’s Team in addition to several additional executive roles. He has over 30 years of direct experience in Academia and Research with a strong understanding of the processes, policies and procedures necessary to attain academic excellence. He continues to provide significant support and leadership to students, faculty, the Academic Senate, division chiefs, department chairs, deans, provosts and the University president on matters relevant to research, academic processes, challenges and growth. He continues to work with faculty, students and staff to strengthen clinical, basic and translational research/programs and integrate them with academic programs across campus and develop strong partnerships with UCLA, Cedars and other institutions. At the request of the University president and deans, he has represented the University at several national forums on cancer and health disparities and he serves in an advisory capacity to the president and the Executive Team for directing research initiatives at CDU in partnership with other institutions.

Strength in Diversity: Dr. Vadgama has over 20 years of experience in working at Historically Black College and University (HBCU) and Hispanic Serving institution (HSI). In 1992/3, he was recruited to Charles R. Drew University of Medicine and Science as Director of Laboratory Research and Development to develop research infrastructure in Biomedical Sciences that supported underrepresented and underserved undergraduate students, graduate students, medical residents, clinical fellows, postdoctoral fellows, and faculty. In addition, during these last 21 years and prior, he has had extensive experience working with underrepresented and under resourced communities in South Los Angeles and neighboring communities. Dr. Vadgama states: “It continues to be an honor and privilege to be able to make differences in the day to day lives of our students, faculty, staff, and community partners.”

Translational Cancer Research Experience: Dr. Vadgama has extensive experience in conducting oncology research that integrates clinical, basic and community-partnered research. The outcome of these efforts has resulted in the development of translational cancer research at CDU. His research team is providing significant leadership in understanding the role of comorbidities such Diabetes and Hypertension in the risk and prognosis for cancer diagnosis and treatment. His group has identified that Obesity contributes significantly to the risk for cancer development and poor clinical outcome. The CDU/UCLA Cancer Center Partnership was recently refunded for over $12.6M (2015-2020) by the National Cancer Institute (U54CA143931) to enhance cancer disparities research at CDU and support programs in developing novel research, sustaining a biomarker identification repository, formal training programs for students, fellows, and faculty, as well as community engagement activities, and clinical research studies. In addition,

Other Professional Experience: Dr. Vadgama serves as reviewer for grants submitted to the NIH, DOD, VHA, and EPSRC. He is Editor-In-Chief of IJBS, and serves on the editorial board of nine journals and an ad-hoc reviewer for 23 peer-reviewed journals. Dr. Vadgama has participated at national and international cancer meetings as chair, co-chair, invited honorary and keynote speaker. In addition, he has served on several community-partnered panels and conferences and was recently honored with a Distinguished Achievement Award for Research and Community Partnership award.

Teaching and Training Experience: Dr. Vadgama has extensive experience in training students, residents and fellows in basic, clinical and translational cancer research. His training programs have been funded from the NIH since 2004 and he serves as mentor and reviewer for several training programs including the CTSI and Susan G. Komen Foundation. To date, Dr. Vadgama has mentored 50 postdoctoral fellows, 13 clinical residents, more than 15 graduate or medical students (mostly underrepresented), more than 110 undergraduate students across the nation, and several high school students. Dr. Vadgama continues to serve as a mentor for several funded early stage investigators at CDU and the UCLA School of Medicine. In addition, he mentors several underrepresented trainees from schools such as CDU, UCLA, UCI, UCR, CSUDH, USC and others.
Education & Training
Teaching
NIH Awarded Grants
Project TitleProject NumberFY
EPIGENOMIC AND GENOMIC FACTORS EMERGING FROM POOR SOCIAL DETERMINANTS OF HEALTH AND THEIR IMPACT ON BREAST CANCER ASSOCIATED WITH OBESITY AND COMORBIDITIES IN AFRICAN AMERICAN AND LATINO WOMEN5U54MD007598-132021
ADMINISTRATIVE CORE5U54MD007598-132021
ACCELERATING EXCELLENCE IN TRANSLATIONAL SCIENCE (AXIS)3U54MD007598-13S22021
ACCELERATING EXCELLENCE IN TRANSLATIONAL SCIENCE (AXIS)5U54MD007598-132021
ADMINISTRATIVE CORE3U54MD007598-13S12021
ADMINISTRATIVE CORE5U54MD007598-132021
ACCELERATING EXCELLENCE IN TRANSLATIONAL SCIENCE (AXIS)3U54MD007598-13S12021
RESEARCH EDUCATION CORE3U54CA143931-10S22020
CDU (ISUPS) ADMINISTRATIVE CORE3U54CA143931-10S22020
CDU-UCLA CANCER CENTER PARTNERSHIP TO ELIMINATE CANCER HEALTH DISPARITIES3U54CA143931-10S22020
EPIGENOMIC AND GENOMIC FACTORS EMERGING FROM POOR SOCIAL DETERMINANTS OF HEALTH AND THEIR IMPACT ON BREAST CANCER ASSOCIATED WITH OBESITY AND COMORBIDITIES IN AFRICAN AMERICAN AND LATINO WOMEN5U54MD007598-122020
ADMINISTRATIVE CORE5U54MD007598-122020
ACCELERATING EXCELLENCE IN TRANSLATIONAL SCIENCE (AXIS)3U54MD007598-12S62020
ACCELERATING EXCELLENCE IN TRANSLATIONAL SCIENCE (AXIS)3U54MD007598-12S12020
ACCELERATING EXCELLENCE IN TRANSLATIONAL SCIENCE (AXIS) - ADMIN SUPPLEMENT3U54MD007598-12S52020
ADMINISTRATIVE CORE3U54MD007598-12S12020
PLANNING AND EVALUATION CORE3U54CA143931-10S22020
ADMINISTRATIVE CORE3U54MD007598-12S52020
RECRUITMENT CORE5U54MD007598-122020
ACCELERATING EXCELLENCE IN TRANSLATIONAL SCIENCE (AXIS)5U54MD007598-122020
SHARED RESOURCES CORE-1: INTEGRATED CLINICAL, TISSUE, AND BIOMARKER DATA BASE CORE (ICTBD CORE)3U54CA143931-10S22020
ACCELERATING EXCELLENCE IN TRANSLATIONAL SCIENCE (AXIS) - ADMINISTRATIVE SUPPLEMENT3U54MD007598-12S32020
ACCELERATING EXCELLENCE IN TRANSLATIONAL SCIENCE (AXIS) - ADMINISTRATIVE SUPPLEMENT3U54MD007598-12S32020
ADMINISTRATIVE CORE3U54MD007598-12S62020
ADMINISTRATIVE CORE3U54MD007598-12S32020
CDU-UCLA CANCER CENTER PARTNERSHIP TO ELIMINATE CANCER HEALTH DISPARITIES5U54CA143931-102019
RECRUITMENT CORE2U54MD007598-112019
EPIGENOMIC AND GENOMIC FACTORS EMERGING FROM POOR SOCIAL DETERMINANTS OF HEALTH AND THEIR IMPACT ON BREAST CANCER ASSOCIATED WITH OBESITY AND COMORBIDITIES IN AFRICAN AMERICAN AND LATINO WOMEN2U54MD007598-112019
ACCELERATING EXCELLENCE IN TRANSLATIONAL SCIENCE (AXIS)2U54MD007598-112019
CDU (ISUPS) ADMINISTRATIVE CORE3U54CA143931-10S12019
CDU-UCLA CANCER CENTER PARTNERSHIP TO ELIMINATE CANCER HEALTH DISPARITIES3U54CA143931-10S12019
SHARED RESOURCES CORE-1: INTEGRATED CLINICAL, TISSUE, AND BIOMARKER DATA BASE CORE (ICTBD CORE)5U54CA143931-102019
CDU (ISUPS) ADMINISTRATIVE CORE5U54CA143931-102019
RESEARCH EDUCATION CORE5U54CA143931-102019
PLANNING AND EVALUATION CORE5U54CA143931-102019
ADMINISTRATIVE CORE2U54MD007598-112019
RESEARCH EDUCATION CORE5U54CA143931-092018
SHARED RESOURCES CORE-1: INTEGRATED CLINICAL, TISSUE, AND BIOMARKER DATA BASE CORE (ICTBD CORE)5U54CA143931-092018
CDU (ISUPS) ADMINISTRATIVE CORE5U54CA143931-092018
CDU (ISUPS) ADMINISTRATIVE CORE3U54CA143931-09S22018
CDU-UCLA CANCER CENTER PARTNERSHIP TO ELIMINATE CANCER HEALTH DISPARITIES - SOCIAL EPIGENOMIC RISK FACTORS FOR CANCER AMONG AFRICAN AMERICANS IN SOUTH LOS ANGELES3U54CA143931-09S22018
ADMIN CORE5U54MD007598-102018
SHARED RESOURCES CORE-1: INTEGRATED CLINICAL, TISSUE, AND BIOMARKER DATA BASE CORE (ICTBD CORE)3U54CA143931-09S12018
CDU (ISUPS) ADMINISTRATIVE CORE3U54CA143931-09S12018
COLLABORATIONS, PARTNERSHIPS AND COMMUNITY CORE5U54MD007598-102018
ACCELERATING EXCELLENCE IN TRANSLATIONAL SCIENCE (AXIS)5U54MD007598-102018
CDU-UCLA CANCER CENTER PARTNERSHIP TO ELIMINATE CANCER HEALTH DISPARITIES - HER2 EXPRESSION IN PROSTATE CANCER DISEASE PROGRESSION AND IDENTIFICATION OF TARGETED THERAPEUTIC INTERVENTION3U54CA143931-09S12018
PLANNING AND EVALUATION CORE5U54CA143931-092018
PLANNING AND EVALUATION CORE3U54CA143931-09S12018
RESEARCH EDUCATION CORE3U54CA143931-09S12018
CDU-UCLA CANCER CENTER PARTNERSHIP TO ELIMINATE CANCER HEALTH DISPARITIES5U54CA143931-092018
RESEARCH EDUCATION CORE5U54CA143931-082017
SHARED RESOURCES CORE-1: INTEGRATED CLINICAL, TISSUE, AND BIOMARKER DATA BASE CORE (ICTBD CORE)5U54CA143931-082017
CDU (ISUPS) ADMINISTRATIVE CORE5U54CA143931-082017
CDU-UCLA CANCER CENTER PARTNERSHIP TO ELIMINATE CANCER HEALTH DISPARITIES5U54CA143931-082017
COLLABORATIONS, PARTNERSHIPS AND COMMUNITY CORE5U54MD007598-092017
ADMIN CORE3U54MD007598-09S12017
PLANNING AND EVALUATION CORE5U54CA143931-082017
ACCELERATING EXCELLENCE IN TRANSLATIONAL SCIENCE (AXIS)3U54MD007598-09S12017
ADMIN CORE5U54MD007598-092017
ACCELERATING EXCELLENCE IN TRANSLATIONAL SCIENCE (AXIS)5U54MD007598-092017
CDU (ISUPS) ADMINISTRATIVE CORE5U54CA143931-072016
PLANNING AND EVALUATION CORE5U54CA143931-072016
ACCELERATING EXCELLENCE IN TRANSLATIONAL SCIENCE (AXIS)3U54MD007598-08S12016
RESEARCH EDUCATION CORE5U54CA143931-072016
SHARED RESOURCES CORE-1: INTEGRATED CLINICAL, TISSUE, AND BIOMARKER DATA BASE CORE (ICTBD CORE)5U54CA143931-072016
ACCELERATING EXCELLENCE IN TRANSLATIONAL SCIENCE (AXIS)5U54MD007598-082016
CDU-UCLA CANCER CENTER PARTNERSHIP TO ELIMINATE CANCER HEALTH DISPARITIES5U54CA143931-072016
RESEARCH EDUCATION CORE2U54CA143931-062015
SHARED RESOURCES CORE-1: INTEGRATED CLINICAL, TISSUE, AND BIOMARKER DATA BASE CORE (ICTBD CORE)2U54CA143931-062015
CDU (ISUPS) ADMINISTRATIVE CORE2U54CA143931-062015
ACCELERATING EXCELLENCE IN TRANSLATIONAL SCIENCE (AXIS)5U54MD007598-072015
CDU-UCLA CANCER CENTER PARTNERSHIP TO ELIMINATE CANCER HEALTH DISPARITIES2U54CA143931-062015
PLANNING AND EVALUATION CORE2U54CA143931-062015
ACCELERATING EXCELLENCE IN TRANSLATIONAL SCIENCE (AXIS)2U54MD007598-062014
CHARLES DREW UNIVERSITY/UCLA CANCER CENTER PARTNERSHIP TO ELIMINATE CANCER HEALTH3U54CA143931-05S22014
CHARLES DREW UNIVERSITY/UCLA CANCER CENTER PARTNERSHIP TO ELIMINATE CANCER HEALTH3U54CA143931-05S12013
PLANNING AND EVALUATION5U54CA143931-052013
ADMINISTRATIVE3U54CA143931-05S12013
ACCELERATING EXCELLENCE IN TRANSLATIONAL SCIENCE (AXIS)5U54MD007598-052013
DEVELOPMENTAL CORE5U54CA143931-052013
CHARLES DREW UNIVERSITY/UCLA CANCER CENTER PARTNERSHIP TO ELIMINATE CANCER HEALTH5U54CA143931-052013
ADMINISTRATIVE5U54CA143931-052013
CHARLES DREW UNIVERSITY/UCLA CANCER CENTER PARTNERSHIP TO ELIMINATE CANCER HEALTH5U54CA143931-042012
ADMINISTRATIVE5U54CA143931-042012
PLANNING AND EVALUATION5U54CA143931-042012
CHARLES DREW UNIVERSITY/UCLA CANCER CENTER PARTNERSHIP TO ELIMINATE CANCER HEALTH3U54CA143931-04S12012
DEVELOPMENTAL CORE5U54CA143931-042012
CHARLES DREW UNIVERSITY/UCLA CANCER CENTER PARTNERSHIP TO ELIMINATE CANCER HEALTH5U54CA143931-032011
PLANNING AND EVALUATION5U54CA143931-032011
DEVELOPMENTAL CORE5U54CA143931-032011
ADMINISTRATIVE5U54CA143931-032011
DEVELOPMENTAL CORE5U54CA143931-022010
CHARLES DREW UNIVERSITY/UCLA CANCER CENTER PARTNERSHIP TO ELIMINATE CANCER HEALTH5U54CA143931-022010
ADMINISTRATIVE5U54CA143931-022010
PLANNING AND EVALUATION5U54CA143931-022010
DREW/UCLA CANCER PARTNERSHIP PROGRAM3U56CA101599-02S32009
DEVELOPMENTAL CORE1U54CA143931-012009
CHARLES DREW UNIVERSITY/UCLA CANCER CENTER PARTNERSHIP TO ELIMINATE CANCER HEALTH1U54CA143931-012009
ADMINISTRATIVE1U54CA143931-012009
PLANNING AND EVALUATION1U54CA143931-012009
DREW/UCLA CANCER PARTNERSHIP PROGRAM3U56CA101599-02S22008
CHARLES R. DREW STUDENT SCHOLAR PROGRAM5R25DK067015-052007
CHARLES R. DREW STUDENT SCHOLAR PROGRAM5R25DK067015-042006
CHARLES R. DREW STUDENT SCHOLAR PROGRAM5R25DK067015-032005
DREW/UCLA CANCER PARTNERSHIP PROGRAM3U56CA101599-02S12005
CHARLES R. DREW STUDENT SCHOLAR PROGRAM5R25DK067015-022004
DREW/UCLA CANCER PARTNERSHIP PROGRAM5U56CA101599-022004
CHARLES R. DREW STUDENT SCHOLAR PROGRAM3R25DK067015-01S12004
CHARLES R. DREW STUDENT SCHOLAR PROGRAM1R25DK067015-012003
DREW/UCLA CANCER PARTNERSHIP PROGRAM1U56CA101599-012003
CORE--CORE LABORATORY3P20RR011145-05S12000
CORE--CORE LABORATORY5P20RR011145-051999
CORE--CORE LABORATORY3P20RR011145-04S21998
CORE--CORE LABORATORY5P20RR011145-041998
CORE--CORE LABORATORY5P20RR011145-031997
MOLECULAR & CELL BIOLOGY CORE LABORATORY: MOLECULAR GENETICS5G12RR003026-111997
Publications
1. Liu D, Vadgama J, Wu Y. Basal-like breast cancer with low TGFß and high TNFa pathway activity is rich in activated memory CD4 T cells and has a good prognosis. Int J Biol Sci. 2021; 17(3):670-682.
  View in: PubMed
 
2. Jimenez T, Friedman T, Vadgama J, Singh V, Tucker A, Collazo J, Sinha S, Hikim AS, Singh R, Pervin S. Nicotine Synergizes with High-Fat Diet to Induce an Anti-Inflammatory Microenvironment to Promote Breast Tumor Growth. Mediators Inflamm. 2020; 2020:5239419.
  View in: PubMed
 
3. Wu Y, Sarkissyan M, Ogah O, Kim J, Vadgama JV. Expression of MALAT1 Promotes Trastuzumab Resistance in HER2 Overexpressing Breast Cancers. Cancers (Basel). 2020 Jul 16; 12(7).
  View in: PubMed
 
4. Hao Q, Vadgama JV, Wang P. CCL2/CCR2 signaling in cancer pathogenesis. Cell Commun Signal. 2020 May 29; 18(1):82.
  View in: PubMed
 
5. Dillard CM, Kiyohara M, Mah V, McDermott SP, Bazzoun D, Tsui J, Chan AM, Haddad G, Pellegrini M, Chang YL, Elshimali Y, Wu Y, Vadgama JV, Kim SR, Goodglick L, Law SM, Patel DD, Dhawan P, O'Brien NA, Gordon LK, Braun J, Lazar G, Wicha MS, Wadehra M. EMP2 is a novel regulator of stemness in breast cancer cells. Mol Cancer Ther. 2020 May 25.
  View in: PubMed
 
6. Dutta P, Paico K, Gomez G, Wu Y, Vadgama JV. Transcriptional Regulation of CCL2 by PARP1 Is a Driver for Invasiveness in Breast Cancer. Cancers (Basel). 2020 May 21; 12(5).
  View in: PubMed
 
7. Keung MY, Wu Y, Badar F, Vadgama JV. Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status. J Clin Med. 2020 Mar 30; 9(4).
  View in: PubMed
 
8. Hao Q, Diaz T, Verduzco ADR, Magyar CE, Zhong J, Elshimali Y, Rettig MB, Henning SM, Vadgama JV, Wang P. Arctigenin inhibits prostate tumor growth in high-fat diet fed mice through dual actions on adipose tissue and tumor. Sci Rep. 2020 Jan 29; 10(1):1403.
  View in: PubMed
 
9. Chung SS, Dutta P, Chard N, Wu Y, Chen QH, Chen G, Vadgama J. A novel curcumin analog inhibits canonical and non-canonical functions of telomerase through STAT3 and NF-?B inactivation in colorectal cancer cells. Oncotarget. 2019 Jul 16; 10(44):4516-4531.
  View in: PubMed
 
10. Keung MYT, Wu Y, Vadgama JV. PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers. J Clin Med. 2019 Mar 30; 8(4).
  View in: PubMed
 
11. Nava M, Dutta P, Farias-Eisner R, Vadgama JV, Wu Y. Utilization of NGS technologies to investigate transcriptomic and epigenomic mechanisms in trastuzumab resistance. Sci Rep. 2019 03 26; 9(1):5141.
  View in: PubMed
 
12. Cao W, Li J, Hao Q, Vadgama JV, Wu Y. AMP-activated protein kinase: a potential therapeutic target for triple-negative breast cancer. Breast Cancer Res. 2019 02 21; 21(1):29.
  View in: PubMed
 
13. Ofili EO, Tchounwou PB, Fernandez-Repollet E, Yanagihara R, Akintobi TH, Lee JE, Malouhi M, Garner ST, Hayes TT, Baker AR, Dent AL, Abdelrahim M, Rollins L, Chang SP, Sy A, Hernandez BY, Bullard PL, Noel RJ, Shiramizu B, Hedges JR, Berry MJ, Bond VC, Lima MF, Mokuau N, Kirken RA, Cruz-Correa M, Sarpong DF, Vadgama J, Yates C, Kahn SA, Soliman KF, Perry G, Pezzano M, Luciano CA, Barnett ME, Oyekan A, Kumar D, Norris KC. The Research Centers in Minority Institutions (RCMI) Translational Research Network: Building and Sustaining Capacity for Multi-Site Basic Biomedical, Clinical and Behavioral Research. Ethn Dis. 2019; 29(Suppl 1):135-144.
  View in: PubMed
 
14. Nava M, Dutta P, Zemke NR, Farias-Eisner R, Vadgama JV, Wu Y. Transcriptomic and ChIP-sequence interrogation of EGFR signaling in HER2+ breast cancer cells reveals a dynamic chromatin landscape and S100 genes as targets. BMC Med Genomics. 2019 02 08; 12(1):32.
  View in: PubMed
 
15. Li J, Hao Q, Cao W, Vadgama JV, Wu Y. Celecoxib in breast cancer prevention and therapy. Cancer Manag Res. 2018; 10:4653-4667.
  View in: PubMed
 
16. Austin D, Hamilton N, Elshimali Y, Pietras R, Wu Y, Vadgama J. Estrogen receptor-beta is a potential target for triple negative breast cancer treatment. Oncotarget. 2018 Sep 21; 9(74):33912-33930.
  View in: PubMed
 
17. Chung SS, Dutta P, Austin D, Wang P, Awad A, Vadgama JV. Combination of resveratrol and 5-flurouracil enhanced anti-telomerase activity and apoptosis by inhibiting STAT3 and Akt signaling pathways in human colorectal cancer cells. Oncotarget. 2018 Aug 31; 9(68):32943-32957.
  View in: PubMed
 
18. Wu K, Yu X, Huang Z, Zhu D, Yi X, Wu YL, Hao Q, Kemp KT, Elshimali Y, Iyer R, Nguyen KT, Zheng S, Chen G, Chen QH, Wang G, Vadgama JV, Wu Y. Targeting of PP2Cd By a Small Molecule C23 Inhibits High Glucose-Induced Breast Cancer Progression In Vivo. Antioxid Redox Signal. 2019 06 10; 30(17):1983-1998.
  View in: PubMed
 
19. Dutta P, Sarkissyan M, Paico K, Wu Y, Vadgama JV. MCP-1 is overexpressed in triple-negative breast cancers and drives cancer invasiveness and metastasis. Breast Cancer Res Treat. 2018 Aug; 170(3):477-486.
  View in: PubMed
 
20. Elshimali YI, Wu Y, Khaddour H, Wu Y, Gradinaru D, Sukhija H, Chung SS, Vadgama JV. Optimization Of Cancer Treatment Through Overcoming Drug Resistance. J Cancer Res Oncobiol. 2018; 1(2).
  View in: PubMed
 
21. Petersen SS, Sarkissyan M, Wu Y, Clayton S, Vadgama JV. Time to Clinical Follow-up after Abnormal Mammogram among African American and Hispanic Women. J Health Care Poor Underserved. 2018; 29(1):448-462.
  View in: PubMed
 
22. Hamilton N, Austin D, Márquez-Garbán D, Sanchez R, Chau B, Foos K, Wu Y, Vadgama J, Pietras R. Receptors for Insulin-Like Growth Factor-2 and Androgens as Therapeutic Targets in Triple-Negative Breast Cancer. Int J Mol Sci. 2017 Nov 02; 18(11).
  View in: PubMed
 
23. Wu Y, Sarkissyan M, Clayton S, Chlebowski R, Vadgama JV. Association of Vitamin D3 Level with Breast Cancer Risk and Prognosis in African-American and Hispanic Women. Cancers (Basel). 2017 Oct 24; 9(10).
  View in: PubMed
 
24. Chung SS, Wu Y, Okobi Q, Adekoya D, Atefi M, Clarke O, Dutta P, Vadgama JV. Proinflammatory Cytokines IL-6 and TNF-a Increased Telomerase Activity through NF-?B/STAT1/STAT3 Activation, and Withaferin A Inhibited the Signaling in Colorectal Cancer Cells. Mediators Inflamm. 2017; 2017:5958429.
  View in: PubMed
 
25. Bhat K, Sarkissyan M, Wu Y, Vadgama JV. GROa overexpression drives cell migration and invasion in triple negative breast cancer cells. Oncol Rep. 2017 Jul; 38(1):21-30.
  View in: PubMed
 
26. Wang P, Solorzano W, Diaz T, Magyar CE, Henning SM, Vadgama JV. Arctigenin inhibits prostate tumor cell growth in vitro and in vivo. Clin Nutr Exp. 2017 Jun; 13:1-11.
  View in: PubMed
 
27. Wu Y, Tran T, Dwabe S, Sarkissyan M, Kim J, Nava M, Clayton S, Pietras R, Farias-Eisner R, Vadgama JV. A83-01 inhibits TGF-ß-induced upregulation of Wnt3 and epithelial to mesenchymal transition in HER2-overexpressing breast cancer cells. Breast Cancer Res Treat. 2017 Jun; 163(3):449-460.
  View in: PubMed
 
28. Chung SS, Adekoya D, Enenmoh I, Clarke O, Wang P, Sarkyssian M, Wu Y, Vadgama JV. Salinomycin Abolished STAT3 and STAT1 Interactions and Reduced Telomerase Activity in Colorectal Cancer Cells. Anticancer Res. 2017 02; 37(2):445-453.
  View in: PubMed
 
29. Wu Y, Yu X, Yi X, Wu K, Dwabe S, Atefi M, Elshimali Y, Kemp KT, Bhat K, Haro J, Sarkissyan M, Vadgama JV. Aberrant Phosphorylation of SMAD4 Thr277-Mediated USP9x-SMAD4 Interaction by Free Fatty Acids Promotes Breast Cancer Metastasis. Cancer Res. 2017 03 15; 77(6):1383-1394.
  View in: PubMed
 
30. Wu Y, Dong Y, Atefi M, Liu Y, Elshimali Y, Vadgama JV. Lactate, a Neglected Factor for Diabetes and Cancer Interaction. Mediators Inflamm. 2016; 2016:6456018.
  View in: PubMed
 
31. Gelfand R, Vernet D, Bruhn KW, Sarkissyan S, Heber D, Vadgama JV, Gonzalez-Cadavid NF. Long-term exposure of MCF-7 breast cancer cells to ethanol stimulates oncogenic features. Int J Oncol. 2017 Jan; 50(1):49-65.
  View in: PubMed
 
32. Chung SS, Oliva B, Dwabe S, Vadgama JV. Combination treatment with flavonoid morin and telomerase inhibitor MST-312 reduces cancer stem cell traits by targeting STAT3 and telomerase. Int J Oncol. 2016 Aug; 49(2):487-98.
  View in: PubMed
 
33. Wang P, Henning SM, Magyar CE, Elshimali Y, Heber D, Vadgama JV. Green tea and quercetin sensitize PC-3 xenograft prostate tumors to docetaxel chemotherapy. J Exp Clin Cancer Res. 2016 May 06; 35:73.
  View in: PubMed
 
34. Gelfand R, Vernet D, Bruhn K, Vadgama J, Gonzalez-Cadavid NF. Long-term exposure of MCF-12A normal human breast epithelial cells to ethanol induces epithelial mesenchymal transition and oncogenic features. Int J Oncol. 2016 Jun; 48(6):2399-414.
  View in: PubMed
 
35. Wu Y, Sarkissyan M, Vadgama JV. Epithelial-Mesenchymal Transition and Breast Cancer. J Clin Med. 2016 Jan 26; 5(2).
  View in: PubMed
 
36. Chung S, Dwabe S, Elshimali Y, Sukhija H, Aroh C, Vadgama JV. Identification of Novel Biomarkers for Metastatic Colorectal Cancer Using Angiogenesis-Antibody Array and Intracellular Signaling Array. PLoS One. 2015; 10(8):e0134948.
  View in: PubMed
 
37. Bazargan M, Lucas-Wright A, Jones L, Vargas R, Vadgama JV, Evers-Manly S, Maxwell AE. Understanding Perceived Benefit of Early Cancer Detection: Community-Partnered Research with African American Women in South Los Angeles. J Womens Health (Larchmt). 2015 Sep; 24(9):755-61.
  View in: PubMed
 
38. Wu Y, Sarkissyan M, Mcghee E, Lee S, Vadgama JV. Combined inhibition of glycolysis and AMPK induces synergistic breast cancer cell killing. Breast Cancer Res Treat. 2015 Jun; 151(3):529-39.
  View in: PubMed
 
39. Hamilton N, Márquez-Garbán D, Mah V, Fernando G, Elshimali Y, Garbán H, Elashoff D, Vadgama J, Goodglick L, Pietras R. Biologic roles of estrogen receptor-ß and insulin-like growth factor-2 in triple-negative breast cancer. Biomed Res Int. 2015; 2015:925703.
  View in: PubMed
 
40. Li Y, Wu Y, Abbatiello TC, Wu WL, Kim JR, Sarkissyan M, Sarkissyan S, Chung SS, Elshimali Y, Vadgama JV. Slug contributes to cancer progression by direct regulation of ERa signaling pathway. Int J Oncol. 2015 Apr; 46(4):1461-72.
  View in: PubMed
 
41. Wang P, Henning SM, Heber D, Vadgama JV. Sensitization to docetaxel in prostate cancer cells by green tea and quercetin. J Nutr Biochem. 2015 Apr; 26(4):408-15.
  View in: PubMed
 
42. Wu Y, Sarkissyan M, Vadgama JV. Epigenetics in breast and prostate cancer. Methods Mol Biol. 2015; 1238:425-66.
  View in: PubMed
 
43. Chung SS, Vadgama JV. Curcumin and epigallocatechin gallate inhibit the cancer stem cell phenotype via down-regulation of STAT3-NF?B signaling. Anticancer Res. 2015 Jan; 35(1):39-46.
  View in: PubMed
 
44. Hamilton N, Marquez-Garban D, Mah VH, Elshimali Y, Elashoff D, Garon EB, Vadgama J, Pietras R. Estrogen Receptor-ß and the Insulin-Like Growth Factor Axis as Potential Therapeutic Targets for Triple-Negative Breast Cancer. Crit Rev Oncog. 2015; 20(5-6):373-90.
  View in: PubMed
 
45. Wang P, Phan T, Gordon D, Chung S, Henning SM, Vadgama JV. Arctigenin in combination with quercetin synergistically enhances the antiproliferative effect in prostate cancer cells. Mol Nutr Food Res. 2015 Feb; 59(2):250-61.
  View in: PubMed
 
46. Wang P, Wang B, Chung S, Wu Y, Henning SM, Vadgama JV. Increased chemopreventive effect by combining arctigenin, green tea polyphenol and curcumin in prostate and breast cancer cells. RSC Adv. 2014 Aug 05; 4(66):35242-35250.
  View in: PubMed
 
47. Sarkissyan S, Sarkissyan M, Wu Y, Cardenas J, Koeffler HP, Vadgama JV. IGF-1 regulates Cyr61 induced breast cancer cell proliferation and invasion. PLoS One. 2014; 9(7):e103534.
  View in: PubMed
 
48. Wu Y, Kim J, Elshimali Y, Sarkissyan M, Vadgama JV. Activation of Akt1 accelerates carcinogen-induced tumorigenesis in mammary gland of virgin and post-lactating transgenic mice. BMC Cancer. 2014 Apr 17; 14:266.
  View in: PubMed
 
49. Sarkissyan M, Wu Y, Chen Z, Mishra DK, Sarkissyan S, Giannikopoulos I, Vadgama JV. Vitamin D receptor FokI gene polymorphisms may be associated with colorectal cancer among African American and Hispanic participants. Cancer. 2014 May 01; 120(9):1387-93.
  View in: PubMed
 
50. Lucas-Wright A, Bazargan M, Jones L, Vadgama JV, Vargas R, Sarkissyan M, Smith J, Yazdanshenas H, Maxwell AE. Correlates of perceived risk of developing cancer among African-Americans in South Los Angeles. J Community Health. 2014 Feb; 39(1):173-80.
  View in: PubMed
 
51. Chung SS, Aroh C, Vadgama JV. Constitutive activation of STAT3 signaling regulates hTERT and promotes stem cell-like traits in human breast cancer cells. PLoS One. 2013; 8(12):e83971.
  View in: PubMed
 
52. Chung SS, Giehl N, Wu Y, Vadgama JV. STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits. Int J Oncol. 2014 Feb; 44(2):403-11.
  View in: PubMed
 
53. Wu Y, Sarkissyan M, Elshimali Y, Vadgama JV. Triple negative breast tumors in African-American and Hispanic/Latina women are high in CD44+, low in CD24+, and have loss of PTEN. PLoS One. 2013; 8(10):e78259.
  View in: PubMed
 
54. Wang P, Vadgama JV, Said JW, Magyar CE, Doan N, Heber D, Henning SM. Enhanced inhibition of prostate cancer xenograft tumor growth by combining quercetin and green tea. J Nutr Biochem. 2014 Jan; 25(1):73-80.
  View in: PubMed
 
55. Elshimali YI, Khaddour H, Sarkissyan M, Wu Y, Vadgama JV. The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients. Int J Mol Sci. 2013 Sep 13; 14(9):18925-58.
  View in: PubMed
 
56. Mishra DK, Wu Y, Sarkissyan M, Sarkissyan S, Chen Z, Shang X, Ong M, Heber D, Koeffler HP, Vadgama JV. Vitamin D receptor gene polymorphisms and prognosis of breast cancer among African-American and Hispanic women. PLoS One. 2013; 8(3):e57967.
  View in: PubMed
 
57. Jones L, Bazargan M, Lucas-Wright A, Vadgama JV, Vargas R, Smith J, Otoukesh S, Maxwell AE. Comparing perceived and test-based knowledge of cancer risk and prevention among Hispanic and African Americans: an example of community participatory research. Ethn Dis. 2013; 23(2):210-6.
  View in: PubMed
 
58. Wu Y, Ginther C, Kim J, Mosher N, Chung S, Slamon D, Vadgama JV. Expression of Wnt3 activates Wnt/ß-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells. Mol Cancer Res. 2012 Dec; 10(12):1597-606.
  View in: PubMed
 
59. Wu Y, Elshimali Y, Sarkissyan M, Mohamed H, Clayton S, Vadgama JV. Expression of FOXO1 is associated with GATA3 and Annexin-1 and predicts disease-free survival in breast cancer. Am J Cancer Res. 2012; 2(1):104-15.
  View in: PubMed
 
60. Sarkissyan M, Mishra DK, Wu Y, Shang X, Sarkissyan S, Vadgama JV. IGF gene polymorphisms and breast cancer in African-American and Hispanic women. Int J Oncol. 2011 Jun; 38(6):1663-73.
  View in: PubMed
 
61. Sarkissyan M, Wu Y, Vadgama JV. Obesity is associated with breast cancer in African-American women but not Hispanic women in South Los Angeles. Cancer. 2011 Aug 15; 117(16):3814-23.
  View in: PubMed
 
62. Wu Y, Shang X, Sarkissyan M, Slamon D, Vadgama JV. FOXO1A is a target for HER2-overexpressing breast tumors. Cancer Res. 2010 Jul 01; 70(13):5475-85.
  View in: PubMed
 
63. Wu Y, Alvarez M, Slamon DJ, Koeffler P, Vadgama JV. Caspase 8 and maspin are downregulated in breast cancer cells due to CpG site promoter methylation. BMC Cancer. 2010 Feb 04; 10:32.
  View in: PubMed
 
64. Mishra DK, Chen Z, Wu Y, Sarkissyan M, Koeffler HP, Vadgama JV. Global methylation pattern of genes in androgen-sensitive and androgen-independent prostate cancer cells. Mol Cancer Ther. 2010 Jan; 9(1):33-45.
  View in: PubMed
 
65. Thant AA, Wu Y, Lee J, Mishra DK, Garcia H, Koeffler HP, Vadgama JV. Role of caspases in 5-FU and selenium-induced growth inhibition of colorectal cancer cells. Anticancer Res. 2008 Nov-Dec; 28(6A):3579-92.
  View in: PubMed
 
66. Wu Y, Mohamed H, Chillar R, Ali I, Clayton S, Slamon D, Vadgama JV. Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer. Breast Cancer Res. 2008; 10(1):R3.
  View in: PubMed
 
67. Padda M, Vadgama J, Sandhu P, Dev A, Giannikopoulos I. Clinical significance of incidental colorectal wall thickening on computed tomography scan in African-American and Hispanic patients. Dig Dis Sci. 2007 Nov; 52(11):3159-64.
  View in: PubMed
 
68. Wu Y, Shen D, Chen Z, Clayton S, Vadgama JV. Taxol induced apoptosis regulates amino acid transport in breast cancer cells. Apoptosis. 2007 Mar; 12(3):593-612.
  View in: PubMed
 
69. Vadgama JV, Scuric Z, Chakrabarti R, Marzo E, Shen D, Wu Y. Insulin-like growth factor I differentially regulates the expression of HIRF1/hCAF1 and BTG1 genes in human MCF-7 breast cancer cells. Int J Mol Med. 2006 Jul; 18(1):129-39.
  View in: PubMed
 
70. Bhat HK, Calaf G, Hei TK, Loya T, Vadgama JV. Critical role of oxidative stress in estrogen-induced carcinogenesis. Proc Natl Acad Sci U S A. 2003 Apr 01; 100(7):3913-8.
  View in: PubMed
 
71. Wu Y, Saldana L, Chillar R, Vadgama JV. Plasma vascular endothelial growth factor is useful in assessing progression of breast cancer post surgery and during adjuvant treatment. Int J Oncol. 2002 Mar; 20(3):509-16.
  View in: PubMed
 
Funding Opportunities

Click terms below for current NIH/NSF funding opportunities.
  • Breast Neoplasms


  • STAT3 Transcription Factor


  • Prostatic Neoplasms


  • Colorectal Neoplasms


  • Hispanic Americans


Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile:
 
Keyword
Last Name
Institution
Department
School
    
 
 
 
Co-Authors  
Lucas-Wright, Anna (Aziza)
Pietras, Richard
Vargas, Roberto
Wang, Piwen
Wu, Yanyuan
See all (10) people
Physical Neighbors  
Sinha-Hikim, Amiya
Ferrini, Monica
Sinha, Satyesh
Chaban, Victor
Wu, Yanyuan


© Charles Drew University of Medicine And Science - Accelerating Excellence In Translational Science (AXIS), All rights reserved.